期刊文献+

阿西替尼对乳腺癌细胞生物学活性的影响 被引量:3

Effects of axitinib on biological activities of breast cancer cells
下载PDF
导出
摘要 目的研究阿西替尼对乳腺癌细胞MCF-7增殖、凋亡和迁移的影响。方法 MTT法检测阿西替尼对MCF-7细胞增殖的影响,流式细胞仪检测阿西替尼作用MCF-7细胞48 h后对细胞周期的影响,并进一步用免疫印迹的方法检测周期蛋白Cyclin D和Cyclin E表达量的变化;流式细胞仪检测阿西替尼对MCF-7细胞凋亡的影响,并用免疫印迹的方法检测凋亡相关蛋白Pro-Caspase-8和Pro-Caspase-9表达水平的变化;Transwell小室实验检测阿西替尼对MCF-7细胞迁移的影响,逆转录-聚合酶链反应(RT-PCR)的方法检测迁移相关蛋白MMP-2和MMP-9表达的变化。结果阿西替尼抑制MCF-7细胞增殖呈时间和剂量依赖性,将MCF-7细胞抑制在G1期,并且G1期调控蛋白随阿西替尼浓度增加表达量逐渐降低;阿西替尼促进MCF-7细胞的凋亡,并且蛋白前体Pro-Caspase-8和Pro-Caspase-9的表达量随阿西替尼浓度的增加而逐渐减少;阿西替尼抑制MCF-7细胞的迁移,迁移相关蛋白MMP-2和MMP-9的m RNA水平随阿西替尼浓度增加而表达下调。结论阿西替尼通过把MCF-7细胞控制在G1期而抑制细胞的增殖,阿西替尼促进MCF-7细胞的凋亡,并能抑制其转移。 【Objective】 To explore the effect of axitinib on proliferation, apoptosis and migration of Michigan Cancer Foundation-7(MCF-7) cells. 【Methods】 The effect of axitinib on cell proliferation was measured by MTT colorimetry. The expression levels of cyclin D and cyclin E proteins were detected by Western blot. The effect of axitinib on cell apoptosis was analyzed using flow cytometry by double staining with annexin V and propidium iodide. The expression levels of pro-Caspase-8 and pro-Caspase-9 proteins associated with apoptosis were detected by Western blot. The invasion potential was evaluated by Transwell assay, and the expression levels of MMP-2 and MMP-9 proteins were measured by RT-PCR. 【Results】 The MCF-7 cell proliferation, apoptosis and invasion were depressed by axitinib in a time or dose-dependent manner. And the levels of associated proteins such as cyclin D, cyclin E, pro-Caspase-8, pro-Caspase-9 and MMP-2, MMP-9m RNA became lower and lower as the axitinib concentration increased.【Conclusion】 Axitinib represses MCF-7 cell proliferation by controlling the cells in G1 stage, triggers cell apoptosis and decreases its invasion potential.
出处 《中国现代医学杂志》 CAS 北大核心 2015年第5期18-23,共6页 China Journal of Modern Medicine
关键词 阿西替尼 MCF-7细胞 增殖 凋亡 迁移 axitinib Michigan Cancer Foundation-7(MCF-7) cell proliferation apoptosis migration
  • 相关文献

参考文献18

  • 1GROSS-GOUPIL M, MASSARD C, RAVAUD A. Targeted thera- pies in metastatic renal cell carcinoma: overview of the past year [J]. Curr Urol Rep, 2011, 13(1): 16-23.
  • 2RINI BI, ESCUDIER B, TOMCZAK P, et al. Comparative effec- tiveness of axitinib versus sorafenib in advanced renal cell carci- noma (AXIS): a randomised phase 3 trial [J]. Lancet, 2011, 378 (9807): 1931-1939.
  • 3COPPIN C, KOLLMANNSBERGER C, LE L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane sys- tematic review of published randomised trials [J]. BJU Int, 2011, 108(10): 1556-1563.
  • 4DUTCHER JP, WILDING G, HUDES GR, et al. Sequential axi- tinib (AG-013736) therapy of patients (pts) with metastatie clear cell renal cell eaneer (RCC) refractory to sunitinib and sorafenib, eytokines and sorafenib, or sorafenib alone [J]. J Clin Oneol, 2008, 26(15): 5127-5132.
  • 5NICKERSON NK, MOHAMMAD KS, GILMORE JL, et al. De- creased autoerine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad[J]. Pies One, 2012, 7(1): 230-255.
  • 6BARTEK J, LUKAS J. DNA damage checkpoints: from initiation to recovery or adaptatian[J]. Current Opinion in Cell Biology, 2007, 19(2): 238-245.
  • 7CHEN-KIANG S. Cell-cycle control of plasma cell differentiation and tumorigenesis[J]. Immunol Rev, 2003, 194(1): 39-47.
  • 8FALCK J, PETRINI JHJ, WILLIAMS BR, et al. The DNA dam- age dependent intra-S phase checkpoint is regulated by parallel pathways[J]. Nature Genet, 2002, 30(3): 290-294.
  • 9CHIANTORE MV, VANNUCCHI S, MANGINO G, et al. Senes- cence and cell death pathways and their role in cancer thera- peutic outcome[J]. Curr Med Chem, 2009, 16(3): 287-300.
  • 10MEIER P, VOUSDEN KH. Lucifer's labyrinth-ten years of path finding in cell death[J]. Mol Cell, 2008, 28(5): 746-754.

同被引文献14

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部